The effectiveness and safety of sacubitril/valsartan in real-world dialysis patients with heart failure reduced ejection fraction.

ABSTRACT:

Backgrounds

Sacubitril/valsartan (angiotensin receptor neprilysin inhibitor [ARNi]) effectively treats heart failure with reduced ejection fraction. Its impact on advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD) remains unclear due to their exclusion from major trials. We aimed to evaluate ARNi's effectiveness and safety in these populations.

Methods

We systematically searched PubMed, Cochrane, Embase, and ClinicalTrials.gov for observational studies of ARNi use in adults with advanced CKD or ESRD requiring maintenance dialysis. Primary outcomes were all-cause mortality and heart failure hospitalization (HHF), with secondary outcomes focusing on left ventricular ejection fraction (LVEF), blood pressure, and biomarkers. A random-effects model was used t

SUBMITTER: Tu KC 

PROVIDER: S-EPMC12863774 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature